We evaluated with an intent-to-treat analysis the response rate, the disease-free survival (DFS), and the overall survival after a multidrug salvage regimen (VIM3ARAC), followed by stem-cell transplantation (SCT) in case of response, in patients with aggressive non-Hodgkin's lymphoma (NHL) who progressed on or after the first-line therapy. Seventy-one patients (refractory: 15; relapse 'on therapy': 36; and relapse 'off therapy': 20) received two courses of VIM3ARAC (teniposide, ifosfamide, mitoxantrone, mitoguazone, high-dose methotrexate, high-dose cytarabine, prednisolone). SCT was performed only in patients with minimal disease after the second course. The response rate was 72%. It was not influenced by response to first-line therapy. Forty-eight patients (68%), including 32 complete responders, fulfilled response criteria for SCT. Thirty-six patients underwent SCT (allogeneic: 3; autologous: 33). The 4-year DFS rate of the 48 responding patients was 39%. The actuarial survival at 4 years was 34% for all patients. Relapse off therapy and a performance status Ͻ2 at relapse were the only two independent favorable prognostic factors for survival. In conclusion, VIM3AraC is associated with a high response rate in relapsing and refractory aggressive NHL. Up to half of the patients could receive SCT. This chemotherapy, followed by SCT could durably salvage 34% of these patients.
Introduction
Although numerous first-line chemotherapy regimens have increased both complete response (CR) rate and long-term survival of patients with aggressive non-Hodgkin's lymphoma (NHL), [1] [2] [3] [4] at least 30 to 40% of patients fail to respond or relapse. Despite an objective response rate of greater than 50%, few patients attain a second response longer than 1 year. 3 Finally, less than 15% of these are alive at 3 years after conventional salvage regimen alone. 3, [5] [6] [7] In contrast, estimated 3-year disease-free survival (DFS) rates of up to 50% have been observed in patients with sensitive disease after conventional salvage regimen, who received high-dose chemotherapy and autologous bone marrow transplantation (ABMT) or peripheral blood (PB) stem cell transplantation (SCT). 5, [8] [9] [10] [11] [12] [13] [14] [15] [16] Moreover, the PARMA study has demonstrated that autologous hematopoietic SCT is associated with a better survival than additional conventional salvage therapy, in patients with recurrent lymphoma sensitive to two initial courses of DHAP. 17 All studies pointed out the lower disease-free survival rates of patients grafted with resistant relapse or refractory NHL. 4, 5 Therefore, we evaluated the effectiveness of a new multidrug salvage regimen (VIM3ARAC), followed by SCT in cases of response, in patients with aggressive NHL who failed after a first-line therapy. We report here an intent-toCorrespondence: P Morel, Service d'Hématologie Clinique, Hô pital Schaffner, 62300 Lens, France; Fax: 33 321 69 13 95 Received 3 July 1998; accepted 12 November 1998 treat analysis on our first 71 patients prospectively included in this study.
Patients and methods
Between June 1988 and October 1993, 71 patients (39 men and 32 women, median age: 37 years, range: 16 to 60), gave their informed consent and were included in this protocol. Eligibility criteria included age less than 60 years, histologically proven refractory or first relapsing aggressive NHL (intermediate or high-grade NHL), World Health Organization (WHO) performance status less than 3, and left ventricular ejection fraction greater than 50%.
Study population (Table 1)
Histological subtypes were intermediate-grade in 49 patients (diffuse small-cleaved cell: 16; diffuse mixed cell: 10; diffuse large-cell: 23) and high grade in 22 patients (diffuse immunoblastic: 10; lymphoblastic 4; Burkitt: 4; anaplastic: 4); according to the International Working Formulation. 18 Immunophenotype was B in 65% of patients, T in 29%, and undetermined in 6%. All patients received a first-line chemotherapy regimen with anthracycline. Fifty-seven patients were included in the LNH84 or the LNH87 protocol: 42 received the ACVBP regimen, 3 10 the NCVBP regimen, 19 and five the mBACOD regimen. 1 Nine patients diagnosed before 1984 received a CHOP regimen, 1 three patients with Burkitt NHL received the LMB protocol, 20 and two patients with lymphoblastic NHL received an ALL protocol. 21 Pretreatment characteristics (Table 1) Fifteen patients (21%) had refractory NHL, defined as failure or minor response (р50%) to front-line therapy. Thirty-six patients (50%) relapsed 'on therapy' (р6 months after the end of chemotherapy) and 20 patients (29%) relapsed 'off therapy' (Ͼ6 months after end of chemotherapy). The relapsing disease involved only initial site of disease in 48 patients, and a new site in 23 patients. The disease was disseminated in 43 patients (65%), and 20 of the 36 patients with stage IV had two or more extranodal sites (ENS). Only eight patients (11%) had histologic marrow involvement. The performance status according to WHO criteria was р1 in 84% of patients and two or three in 16% of patients. Lactate dehydrogenase was increased in 63% of patients. No modification in chemotherapy dosage was foreseen but the courses were initiated every 28 days, or when polymorphonuclears increased to Ͼ1.0 × 10 9 /l, and platelets to Ͼ100 × 10 9 /l. The last 20 patients received filgastrim (Amgen Biologicals, Thousand Oaks, CA, USA).
Evaluation of toxicity, response and criteria for SCT
Toxicity was graded according to the WHO criteria. Evaluation of response was planned after the second cycle. The disappearance of all evidence of disease during at least 1 month defined CR. A persisting mass, stable for at least 2 months defined partial reponse with residual mass. More than 75% of tumor reduction or partial response with residual mass defined good partial response (GPR), more than 50% of tumor reduction defined partial response (PR). Failure was defined as the absence of tumor reduction or a progression during chemotherapy. SCT was performed only in patients with minimal disease (MD). Criteria for MD were either CR or GPR. Patients who did not achieve MD, patients with WHO performance status Ͼ2 and patients with poor stem cell harvest were excluded from the protocol.
Conditioning regimen and SCT
Three patients underwent an allogeneic SCT, 24 an ABMT, and nine a peripheral blood SCT. The bone marrow or granulocyte colony-stimulating factor (G-CSF) primed peripheral blood stem cell rescues were collected after the second cycle of VIM3ARAC. The conditioning regimen consisted of fractionated total body irradiation (12 Gy, six fractions in 3 days) with cyclophosphamide (60 mg/kg on 2 consecutive days) in 
Statistical analysis
Endpoints were the rate of response to the VIM3AraC regimen; the DFS, measured from the day of response to VIM3ARAC until disease progression or end of follow-up or death, for all CR patients, and the overall survival, measured from the first day of delivery of the VIM3AraC regimen to the end of followup or death. Failure-free survival was measured from the first day of delivery of the VIM3AraC regimen to progression, relapse, the end of follow-up or death. Survival rates were estimated by the product-limit method of Kaplan and Meier, and were compared by the log-rank test. 23 The parameters significant at the 0.05 level for survival were introduced in a proportional hazards model regression analysis (Cox model) with forward stepwise selection.
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Results
Seventy-one patients received a total of 158 cycles. Nine patients received only one cycle because of early death (one patient), progression (five patients), WHO grade 4 infectious toxicity (one patient), early response and SCT after the first cycle (two patients). Thirty-seven patients received two cycles and 25 received three cycles.
Reponse to VIM3ARAC
Because of the early death of one patient, an evaluable response was present in 70 patients only. Thirty-two patients achieved a CR (45%), 16 a GPR (23%), three (4%) a PR after the second cycle. Nine (13%) patients failed to respond and 10 (15%) progressed during chemotherapy. Finally, the overall response rate (CR, GPR and PR) was 72.8% (95% confidence interval (CI): 71.6-74%), and 68.5% (95% CI: 67.2-69.8%) of patients fulfilled response criteria for SCT (CR and GPR). Histology, immunophenotype, age, LDH, Ann Arbor stage, performance status, the number of extranodal sites, bone marrow involvement at relapse, and response to first-line therapy did not influence response to VIM3AraC. However, response rate was higher in patients who relapsed off-therapy (P = 0.01). Indeed 11 (78%) of the 14 evaluable patients refractory to first-line therapy, 19 (53%) of the 36 patients who relapsed on therapy, and 18 (90%) of the 20 patients who relapsed later achieved a minimal disease after VIM3AraC.
Twenty-one of the 22 evaluable patients who failed to achieve CR or GPR died of progressive disease 3 to 52 months after the diagnosis of relapse (median 11 months). The remaining patient was alive in PR at 30 months.
Toxicity of VIM3ARAC (Table 2)
A grade 4 leukopenia or thrombocytopenia was observed in all patients. A grade Ͼ2 infection occurred during the first cycle in 10 patients and another patient died from septic shock. The incidence of infection, the number of hospital and i.v. antibiotherapy days were not influenced by performance status or by the use of filgastrim. The second cycle was initiated later for patients who did not receive filgastrim (2.5 vs 0.5 days; P = 0.03).
A grade 2 hepatic toxicity and a grade 2 renal toxicity were found in one and two patients, respectively.
Delivery of SCT in the 48 patients with MD after VIM3AraC
Thirty-six patients (51%) underwent an SCT (allogeneic: three; autologous: 33) 3 to 6 months after the diagnosis of progression (median: 4.9 months). Among the 48 patients with MD after VIM3AraC, SCT could be performed in six (54%) of the 11 refractory patients, 14 (73%) of the 19 patients with relapse on-therapy, and 16 (88%) of the 18 patients with relapse off-therapy.
Twelve patients responded to VIM3ARAC regimen but were not autografted because of early relapse (four patients), refusal (two patients), poor marrow harvest (one patient) and poor performance status after chemotherapy (five patients). Two of the 12 patients were alive in CR or GPR at 14 and 43 months. Another responding patient died at 24 months because of therapy-related myelodysplastic syndrome. The remaining nine patients died of progressive disease.
Toxicity of SCT after VIM3AraC
The median time to reach self-sustaining granulocyte recovery Ͼ0.5 × 10 9 /l and median time for platelet recovery One patient developed a grade 3 chronic hepatic graft-versus-host disease (GVHD), the two other allografted patients had transient grade 1 or 2 GVHD.
Twenty-four infections were recorded (grade 1, 14; grade 2, seven; and grade 3, three patients). One patient had blood cultures positive for Candida tropicalis. A lethal cardiogenic shock occurred on day 28 after ABMT. Two grade 3, three grade 2 mucositis, and a grade 3 cutaneous toxicity (caused by vancomycin) were recorded. Two late grade 2 renal toxicity occurred, including a hemolytic-uremic syndrome after autologous SCT. A patient who developed a secondary acute myelogenous leukemia with t(8;21) 5 months after graft has been reported elsewhere. 25 Another patient died 23 months after SCT from a pneumonia caused by cytomegalovirus associated with a severe hypogammaglobulinemia.
Evolution of the 36 grafted patients
Two of the three allografted patients relapsed 3 months after transplantation and died of progressive disease, the remaining patient was alive in CR at 53 months with a severe GVHD. Response after autologous SCT was evaluable in 32 patients (one patient died early). Sixteen patients were alive in CR including 14 patients in second CR for 8 to 78 months (median, 30 months) and two in third CR at 1 and 57 months after the second relapse. These patients relapsed at 63 and 9 months, respectively. The latter patient underwent a second SCT after cyclophosphamide and total body irradiation. Another patient relapsed at 13 months. He was alive in partial response at the stopping date. Fourteen patients relapsed and died of progressive disease 3 to 38 months after SCT (median, 5 months), including the patient who developed a secondary acute myelogenous leukemia 10 months before relapse. The last patient died from pneumonia caused by cytomegalovirus.
Finally, 18 of the 36 grafted patients were alive, namely three of the six refractory patients, five of the 14 patients who relapsed on therapy, and 10 of the 16 patients with relapse off-therapy who were grafted. The DFS and the actuarial survival at 4 years were estimated 45% (95% CI: 29-61%) and 55% (95% CI: 39-71%) respectively, with a median followup of 32 months after SCT. (Figures 1, 2, 3 
Disease-free survival, failure-free survival, and overall survival of the 71 patients
and 4, Table 3)
The 4-year DFS rate of the 48 responding patients was 39% (95% CT: 25-53%). The failure-free survival at 4 years was 27% (95% CI: 17-37%), and the actuarial survival at 4 years was 34% (95% CI: 23-45%), with a median follow-up of 16 months for all patients.
We found no prognostic factor for DFS. The five patients with a poor performance status at relapse who responded to VIM3AraC had a shorter response duration (median, 3 vs 22.9 months) without statistical significance (P = 0.18) probably because of their small number. An increased LDH level at relapse (P = 0.029), a poor performance status (P = 0.03), and early relapse (refractory or relapse on, P = 0.01, Figure 4 ), were associated with a poor survival. Early relapse and poor performance status were the only two independent adverse prognostic factors for survival in a Cox model. The survival of 
Figure 1
Complete remission duration after VIM3Ara-C of the 48 responding patients. Seventeen patients were disease-free at 36 months.
patients who achieved a minimal disease (CR, or PR with residual mass or PR Ͼ75%) after VIM3AraC was not influenced by the importance of the response (CR vs GPR). Univariate analyses of survival and Cox model yield the same results when there were performed in the subgroup of 46 patients with diffuse mixed, diffuse large cell, immunoblastic or anaplastic NHL.
Discussion
The present study showed that the VIM3AraC regimen, used as first salvage therapy, allowed SCT in 51% of patients with aggressive NHL. Finally, 34% of patients were alive after VIM3AraC.
Since the response rate was 68% with a CR rate of up to
Figure 2
Failure-free survival of the 71 patients. Eighteen patients were failure-free at 36 months.
Figure 3
Overall survival after VIM3Ara-C of the 71 patients. Twenty-three patients were alive at 36 months.
Figure 4
Overall survival after VIM3Ara-C according to the type of relapse: Ref, refractory; relapse on-therapy or refractory, 11 patients alive at 36 months; relapse off-therapy, 12 patients alive at 36 months.
45%, we confirmed our preliminary results in a large homogeneous series. 26 Although 55 to 87% of NHL patients responded to previous salvage chemotherapy regimens, only 27 to 37% of these achieved a CR. The favorable prognostic value of a prolonged duration of the first CR for response to salvage therapy had already been pointed out. 6 Several statistics suggested that a previous CR 27, 28 favorably influenced the response rate on salvage therapy, whereas the response to first-line therapy did not influence response rate on VIM3A-RAC. Likewise, initial response did not influence response rate on DHAP. 7 We found no other prognostic factor for response to VIM3AraC, whereas, LDH at relapse, 6, 7, 27 bulky disease, 6, 7 number of extra-nodal sites of disease, 6 bone marrow involvement 6 have retained a prognostic value for response to other salvage therapy. However, the present series should be compared with previous reports cautiously, because the latter included patients with low-grade NHL, or with two or more previous regimens. Treatment-related mortality in the present series was minimal, despite the severe myelosuppression observed with VIM3AraC in all the patients. The use of hematopoietic growth factors yields only a better delivery of VIM3-AraC. In addition, the bone marrow or G-CSF-primed blood stem cell rescues collected during VIM3ARAC allowed all except one patient to be transplanted with a minimal SCTrelated mortality.
The 39% 4-year DFS rate of the present series, analyzed on an intent-to-treat basis, should only be compared to the 46% 4-year event-free survival (EFS) rate of the responding patients randomized in the transplantation group of the PARMA study, 17 and to the 38% 2-year EFS rate observed after the arm B of the recently reported LNH RP 93 study, 30 which included high-dose cyclophosphamide and etoposide, VIM2AraC (etoposide, ifosfamide, mitoxantrone, and cytosine arabinoside) and ICE (ifosfamide, carboplatin, and etoposide) intensive therapy in case of response. Indeed, other series included only transplanted patients. They provided estimations of DFS, event-or progression-free survival at 3 years, ranging from 50% in patients with sensitive disease at time of transplant 9, 22, 29, 31 to 70 or 80% in CR patients, 32, 33 whereas the DFS of our grafted patients with CR or PR Ͼ75% was estimated 45% at 3 years. A responsive disease, 9, 12, 22, 29, 31, 33 or complete remission at time of transplant, 32 are favorable prognostic parameters for the duration of response after SCT, and low tumor burden before SCT is associated with a better survival. 5, 7, 27 Moreover, the LNH RP 93 study 30 indicated that patients in CR before SCT had a better EFS and overall survival than patients not in CR, and that patients treated by VIM2AraC before SCT had a higher 2-year EFS than patients treated without VIM2AraC.
The 34% overall survival rate at 4 years agreed with the 44% estimated 2-year survival reported in the 28 patients of the arm B of the LNH RP 93. Sixty-eight percent of these patients received ICE intensive therapy. 30 The present overall survival rate appears lower than the 53% survival rate observed at 5 years in the 55 patients of the transplantation group of the PARMA study. 17 However, the PARMA series included five patients at the time of the second relapse of their NHL, but enrolled no refractory NHL, nor NHL with bone marrow involvement at the time of the relapse. In addition, the survival reported by the PARMA group started at the date of randomization, after the two initial cycles of DHAP. It took the six patients who responded to DHAP but received no tranplantation into account, but not the 42% non-responding patients. Thus, these two analyses on an intent-to-treat basis should be compared with caution.
As previously found in series of patients treated with conventional chemotherapy, [3] [4] [5] we found that the duration of the previous remission is one of the most important prognostic factors for survival after relapse in patients treated by VIM3A-raC and SCT in case of response.
The reasons for the better survival of patients with good per-formance status, without DFS and response rate advantage are uncertain. One possibility is a better delivery of the intensive chemotherapy in cases of good performance status. However, the infectious toxicity, and hospital stays were not more frequent in patients with poor performance status. Another explanation might be that poor performance status at relapse is associated with a more aggressive NHL. This second hypothesis agreed with the adverse prognostic value of poor performance status for freedom from second progression reported by Bosly et al. 5 Thus poor performance status should not preclude an intensive treatment approach.
In summary, a high proportion of patients achieved a minimal disease status-a well-known favorable prognostic factorafter VIM3Ara-C regimen, even in cases of primary refractory aggressive NHL. Seventy-five percent of these responding patients could undergo a stem cell transplantation with the same post-transplant survival as previously described. Although these results might support the use of VIM3AraC, the management of these patients needs to be improved. Future studies should be conducted to determine the roles of bone marrow purging, new conditioning regimen, post-transplant immunomodulation, or tandem transplants, 34 especially in patients with relapse on therapy, or poor performance status.
In conclusion, the present analysis indicated that VIM3AraC is an effective regimen for relapsing and for refractory aggressive NHL. This chemotherapy, followed by autologous SCT could durably salvage 34% of patients at the time of the first relapse or with refractory aggressive NHL, analyzed on an intention-to-treat basis.
